S. Verjee

Journal of Clinical Oncology · 2006

A researcher in the Science corpus: 1 paper; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from S. Verjee's perspective

Ordered by how strongly the researchers S. Verjee trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (New England Journal of Medicine)
  2. Individual Comparisons by Ranking Methods
  3. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. (Journal of Clinical Oncology)
  4. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. (American Journal of Pathology)
  5. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. (Cancer Research)
  6. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. (Journal of the National Cancer Institute)
  7. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. (New England Journal of Medicine)
  8. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. (Journal of Clinical Oncology)
  9. Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. (Journal of Urology)
  10. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). (Journal of the National Cancer Institute)

Their papers